Worldwide Molecular Analysis Of Streptococcus Pyogenes Scarlet Fever Outbreaks
Funder
National Health and Medical Research Council
Funding Amount
$544,041.00
Summary
The microorganism group A Streptococcus (also called GAS or Streptococcus pyogenes) ranks among the top 10 infectious disease killers of humans. Recently, outbreaks of scarlet fever have occurred in both Asia and the United Kingdom, placing a serious strain on health systems. The reasons underlying these outbreaks remain unknown. Our team will lead the global effort to characterise this rise in scarlet fever, and provide recommendations and solutions to health professionals.
E. coli is a normal inhabitant of the human intestine, but some varieties can cause serious infections that may lead to the premature death of children, especially in less developed countries. The aims of this study are to learn more about these harmful varieties of E. coli and to enhance our ability to detect them in samples from patients and the environment.
Interactions Between Host And The Gut Microbiome In The Pathogenesis Of Ankylosing Spondylitis And Crohn's Disease
Funder
National Health and Medical Research Council
Funding Amount
$572,227.00
Summary
Ankylosing spondylitis (AS) and Crohn's disease (CD) are common immune-mediated diseases affecting primarily the joints of the spine and the gut respectively. Genes play a major role in determining the risk of each disease, and it is likely that those genes cause the disease by interaction with some environmental factor, most likely bacteria residing in the gut. This study aims to test that hypothesis by profiling the bacteria in the gut of patients with the diseases and healthy subjects.
Is Mycobacterium Ulcerans A Zoonotic Agent Spread By Mosquitoes?
Funder
National Health and Medical Research Council
Funding Amount
$335,853.00
Summary
Last year record numbers of a mysterious flesh-eating bacterial disease called Buruli ulcer were reported in Australia. Wild animals such as possums and rats harbour the bacteria in their guts but we don't know how the disease is transmitted to humans. In this project we will work out how the bacteria survives in the guts of animals and how people contract Buruli ulcer. With this information we can stop the spread of this debilitating disease.
Combating E. Coli Diarrhoea By Disarming Bacterial Virulence
Funder
National Health and Medical Research Council
Funding Amount
$674,737.00
Summary
E. coli causes severe and persistent diarrhoea which affects the health of millions of people worldwide. Although antibiotics may alleviate E. coli diarrhoea, these bacteria are becoming resistant to most drugs. In this study, we will use state-of-the-art technology to discover novel types of drug that treat and prevent infection with E. coli, without harming the beneficial bacteria in the gut.
Interaction Of Group A Streptococci With Intracellular Innate Immune Defence
Funder
National Health and Medical Research Council
Funding Amount
$824,252.00
Summary
The pathogenic bacterium group A streptococcus (GAS) is estimated to cause ~700 million cases of self-limited throat or skin infection each year worldwide. GAS infections result in over 600,000 human deaths. This disease burden places GAS in the “top 10” causes of human infectious disease deaths worldwide. We have discovered a hitherto unknown mechanism by which GAS subvert the human immune system. An improved understanding of this mechanism will lead to novel ways to combat GAS infections.
A Novel Therapeutic Target For Preventing Helicobacter Pylori-associated Diseases
Funder
National Health and Medical Research Council
Funding Amount
$750,336.00
Summary
Gastric cancer mainly results from chronic inflammation (gastritis) caused by the stomach-dwelling bacterium, Helicobacter pylori. We have identified a potassium channel which our data suggest could be a new therapeutic target for protecting against gastric cancer caused by H. pylori infection. This project will test the role of this channel in H. pylori gastritis and see whether drugs that target this channel can protect mice against H. pylori-associated disease.
Group A streptococcus (GAS) is a bacteria that causes a wide range of disease in humans. GAS diseases are more common in Australias Indigenous population, and other health and economically disadvantaged groups than more affluent groups. In this study we will evaluate the effectiveness of novel vaccine candidates designed to prevent infection from all strains of GAS.
Host Cell Death Signaling And Susceptibility To Bacterial Gut Infection
Funder
National Health and Medical Research Council
Funding Amount
$682,321.00
Summary
Bacterial infections are a major cause of infectious disease worldwide. Here we aim to characterise immune responses that help fight infection by E. coli and Salmonella. These bacteria have evolved ways to shut down many of our immune responses during infection, allowing them to survive and cause disease. This work will help understand the complex relationship between gut bacteria and our immune system and provide solutions for controlling infection and treating immune disorders of the gut.
Novel Epigenetic Regulatory Mechanisms In Moraxella Catarrhalis And Non-typeable Haemophilus Influenzae: Impact On Vaccine Development And Role In Pathobiology
Funder
National Health and Medical Research Council
Funding Amount
$626,979.00
Summary
Moraxella catarrhalis (Mcat) and non-typeable Haemophilus influenzae (NTHI) are two major causes of middle ear infections in children, and respiratory disease in adults. This project aims to characterise novel regulatory mechanisms associated with disease isolates of these bacteria. This research will aid vaccine development by defining the repertoire of stably expressed potential vaccine targets of Mcat and NTHi, and will improve our understanding of host-pathogen interactions.